Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Adma Biologics (ADMA) over the last 6 years, with Sep 2025 value amounting to $2.6 million.

  • Adma Biologics' Other Accumulated Expenses fell 22.71% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 22.71%. This contributed to the annual value of $2.0 million for FY2024, which is 15.60% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Other Accumulated Expenses is $2.6 million, which was down 85.35% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Other Accumulated Expenses peaked at $17.5 million during Q2 2025, and registered a low of $981,721 during Q4 2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $2.4 million (2023), whereas its average is $3.8 million.
  • As far as peak fluctuations go, Adma Biologics' Other Accumulated Expenses crashed by 33.89% in 2023, and later spiked by 663.13% in 2025.
  • Adma Biologics' Other Accumulated Expenses (Quarterly) stood at $981,721 in 2021, then soared by 82.94% to $1.8 million in 2022, then spiked by 31.68% to $2.4 million in 2023, then declined by 15.60% to $2.0 million in 2024, then dropped by 22.71% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $17.5 million for Q2 2025, and $2.0 million during Q1 2025.